Literature DB >> 19772372

Emerging apoptosis agonists for bladder cancer.

Chris Protzel1, Oliver W Hakenberg.   

Abstract

Bladder cancer is a very common and aggressive tumor entity. Unfortunately, common chemotherapy is not able to cure advanced bladder cancer. Therefore, several attempts have been made to improve the response to chemotherapy. Because changes in apoptotic pathways are frequent events in the development of chemoresistance of malignancies, pro-apoptotic treatment seems promising for the improvement of bladder cancer prognosis. Preclinical data show potential ways for a successful combination of apoptosis agonists with conventional chemotherapy. None of these principles has so far successfully been translated into clinical trials for bladder cancer. This review describes actual studies and future perspectives for apoptotic agonists in bladder cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19772372     DOI: 10.1517/14728210903251708

Source DB:  PubMed          Journal:  Expert Opin Emerg Drugs        ISSN: 1472-8214            Impact factor:   4.191


  3 in total

1.  [Molecular markers in the diagnostics and therapy of urothelial cancer].

Authors:  C Protzel; O W Hakenberg
Journal:  Urologe A       Date:  2010-11       Impact factor: 0.639

Review 2.  Molecular research in penile cancer-lessons learned from the past and bright horizons of the future?

Authors:  Chris Protzel; Philippe E Spiess
Journal:  Int J Mol Sci       Date:  2013-09-26       Impact factor: 5.923

Review 3.  Putting the Brakes on Tumorigenesis with Natural Products of Plant Origin: Insights into the Molecular Mechanisms of Actions and Immune Targets for Bladder Cancer Treatment.

Authors:  Qiushuang Wu; Janet P C Wong; Hang Fai Kwok
Journal:  Cells       Date:  2020-05-13       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.